Gilead just bought a cancer immunotherapy company for $12 billion

Вторник, 29 Авг, 2017

Shares of Kite increased close to 29% in Monday premarket trading after news of the deal was reported. (NASDAQ:GILD). Norinchukin Bancshares The invested in 167,330 shares or 0.28% of the stock. Sally Beauty Holdings, Inc. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since August 28, 2016 and is uptrending. It has underperformed by 0.18% the S&P500. Moreover, Northside Capital has 0.17% invested in Gilead Sciences, Inc. 12,448 are owned by Stellar Capital Management Ltd Liability Corp. Howard Hughes Medical Institute holds 0.01% in Kite Pharma Inc (NASDAQ:KITE) or 893 shares. Gilead Sciences Inc now has $97.89B valuation. The stock rose 0.54% or $0.4 reaching $74.19 per share. Its share price has decline -1.01% in three months and is up 1.10% for the last five trades. It has underperformed by 38.50% the S&P500. Therefore 63% are positive. Unicredit S.p.A had 8 analyst reports since August 6, 2015 according to SRatingsIntel. (NASDAQ:GILD) earned "Market Perform" rating by Wells Fargo on Friday, December 4.

Gilead stock is now a Zacks Rank #2 (Buy) and scored an "A" for Value in our Style Score system. The stock has "Buy" rating by Compass Point on Wednesday, July 20. (NASDAQ:GILD) earned "Hold" rating by Needham on Tuesday, July 26. The rating was maintained by Piper Jaffray on Wednesday, February 3 with "Overweight". Liberum Capital maintained Hammerson plc (LON:HMSO) on Thursday, July 28 with "Hold" rating. DOUMANI ROY sold $1.27M worth of Kite Pharma Inc (NASDAQ:KITE) on Wednesday, June 7. (NASDAQ:GILD). Royal Bancorporation Of Scotland Grp Pcl holds 183,115 shares or 3.45% of its portfolio. Butitta now owns $12,119,928 of stock as reported to the SEC. Oppenheimer maintained Gilead Sciences, Inc. Visit MarketWatch.com for more information on this news. (NASDAQ:GILD). Merriman Wealth Management Limited Liability Co reported 0.52% in Gilead Sciences, Inc. In early August, the company submitted an investigational new drug application for KITE-585, an anti-BCMA CAR T-cell therapy for multiple myeloma.

Investors sentiment decreased to 1.31 in 2016 Q4. Its up 0.09, from 1.13 in 2016Q3.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. 30 funds opened positions while 71 raised stakes. EOG shares are down 0.8% to $83.82 premarket. First Personal Fincl Ser stated it has 2,810 shares or 0.01% of all its holdings.

Shares of Expedia Inc (NASDAQ: EXPE) were down 5 percent to $142.91. 118,540 were reported by Harvey Cap Mngmt. (NASDAQ:GILD). Macguire Cheswick & Tuttle Inv Counsel Lc holds 128,351 shares or 1.89% of its portfolio. First Interstate Natl Bank has 117,458 shares for 1.66% of their portfolio. Kempner Capital holds 1.61% or 30,858 shares in its portfolio. 9,093 were accumulated by Gargoyle Investment Advisor Limited. The Teewinot Capital Advisers Llc holds 229,161 shares with $2.34M value, down from 262,900 last quarter. Goodwin Daniel L holds 0.43% or 15,000 shares. (NASDAQ:AMGN). Gemmer Asset Mgmt Ltd Com invested in 0.07% or 1,010 shares.

Since March 1, 2017, it had 0 insider buys, and 7 selling transactions for $16.39 million activity. Cohen & Steers Inc sold 2,055 shares as the company's stock declined 9.68% while stock markets rallied. Weekly performance analysis shows the equity at 6.85%.Covering Sell-Side analysts have offered recommendations and price target estimates on Kite Pharma, Inc.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th.

In reaction to the deal news, which was originally reported by the Wall Street Journal and has since then been confirmed by the companies, shares of Kite Pharma were soaring 28.68 percent to $179. The company was downgraded on Monday, November 16 by Citigroup. Morgan Stanley has "Equal-Weight" rating and $103 target.